The ESV principals provided useful feedback on new ideas emerging from faculty inventors. The faculty presenters and technologies included:

• New method fabricates decellularized human extracellular matrix morsels for tissue regeneration, especially after myocardial infarction. Blanche Ip, PhD, Assistant Professor of Molecular Pharmacology, Physiology and Biotechnology (research). Jeffrey R. Morgan, PhD, Professor of Medical Science and Professor of Engineering.
• Novel technology uses synthetic oligonucleotides to target and knock out expression of specific enhancer RNAs in glioma stem cells that are correlated with decreased survival in glioblastoma patients. Nikos Tapinos, MD, PhD, Associate Professor of Neurosurgery (research).
• A novel diagnostic technology to detect normal-pressure hydrocephalus (NPH), which is often misdiagnosed as neurodegenerative diseases such as Alzheimer’s. Alexander Fleischman, PhD, Provost’s Associate Professor of Brain Science.
• A 3D in vitro screening platform for toxicity testing uses stem cell-derived human cardiac microtissues to quantify dose-dependent changes in electrical activity. Kareen L. K. Coulombe, PhD, Assistant Professor of Engineering and Assistant Professor of Molecular Pharmacology. 
• Research by Justin Fallon enabled Startup Bolden Therapeutics’ development of treatment for central nervous system diseases based on stimulation of endogenous neural stem cells to promote neurogenesis. Justin Fallon, PhD, Professor of Neuroscience and Professor of Psychiatry and Human Behavior.